What the buyer needs
AI summaryThe Department of Veterans Affairs, Network Contracting Office 4 intends to award a firm-fixed-price sole source contract to Novartis Pharmaceuticals Corporation to procure and deliver name brand radiopharmaceuticals Lutathera and Pluvicto to the Lebanon VA Medical Center. The scope requires delivery, storage, inventory management, packaging, shipment preparation, distribution, and transportation of ready-to-use unit doses in lead-shielded containers, alongside handling returns and hazardous material disposal. Capable vendors with up to 1,300 employees under NAICS code 325412 may submit a one-page capability statement by November 3, 2026, at 14:00 EST. Submissions must be emailed to the Contracting Specialist and include the company name, SAM UEI number, socioeconomic category, and a brief description of capabilities. The Government will evaluate responses to determine whether to compete the requirement or proceed with sole-source negotiations.
Scope of work
- Procurement and delivery of Lutathera (lutetium Lu177 dotatate) infusion dose (200mCi)
- Procurement and delivery of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) infusion dose (200mCi)
- Storage, inventory management, packaging, and shipment preparation in ready-to-use unit doses
- F.O.B. Destination routine and emergency radiopharmaceutical delivery to Nuclear Medicine Room G025
- Pick up of scheduled used and unused items for proper disposal at no cost
- Consultation services regarding radiopharmaceutical applications, problems, and controls upon request
- Access to relevant online and/or live initial and continuing education for Lebanon VAMC personnel
- Provision of miscellaneous services on an as-needed basis including survey meter and dose calibrator calibrations
Minimum qualifications
- Must be licensed by the Nuclear Regulatory Commission (NRC) and/or agreement state for radioactive materials
- Must hold an FDA license to produce and distribute radiopharmaceuticals for human administration
- Must be regularly established in the business of providing Lutathera and Pluvicto at the necessary scale and frequency
- Must provide evidence of special driver's licenses (competency) for transporting hazardous materials
- Must maintain compliance with NRC, VA/NHPP, DOT, FDA, and OSHA requirements
Documents to include with your response
- Capability statement
- Copy of radioactive material license
- Regular work hours and telephone contact instructions for regular and emergency orders
- Evidence of special driver's licenses for transporting hazardous materials
How to submit
- Method
- Instructions
- Responses must be sent via email to the Contracting Specialist; capability statement must be no more than one page in length.
Incumbent and award research
Likely prior awards for this requirement
Likely matchAwarded by the same buying office (36C244) with descriptions matching "lutathera". The notice does not name its current contract, so confirm before relying on it.
| Vendor and award | Value | Ends |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION36C24426F0063 · RADIOPHARMACEUTICALS-LUTATHERA AND PLUVICTO INJECTIONS | $2.0M | Dec 31, 2026 |
| ADVANCED ACCELERATOR APPLICATIONS USA INC36C24425F0144 · LUTATHERA & PLUVICTO ISOTOPES | $84,994 | Dec 31, 2025 |
Market context
Awards in the same category (Pharmaceutical Preparation Manufacturing). This is not this requirement's award history.
Recent similar awards: Department of Veterans Affairs, NAICS 325412
| Vendor and award | Value | Ends |
|---|---|---|
| PHARMALOGIC LTD36C24126P0126 · RADIOPHARMACEUTICALS | $135.8K | Dec 31, 2030 |
| CARDINAL HEALTH 414, LLC36C24126P0009 · RADIOPHARMACEUTICALS | $70,000 | Nov 25, 2030 |
| EXELAN PHARMACEUTICALS INC36C24226N0564 · LENALIDOMIDE | $3.1M | May 31, 2029 |
| CARDINAL HEALTH 414, LLC36C26224P0890 · RADIOPHARMACEUTICALS BASE PLUS FOUR OPTION YEARS | $1.4M | Feb 28, 2029 |
| RLS (USA) INC.36C26224P0297 · RADIOPHARMACEUTICALS | $1.1M | Nov 30, 2028 |
Top vendors in this category: Department of Veterans Affairs, NAICS 325412, since Oct 1, 2024
4,151 contract awards in this NAICS over the period.
- 1. MCKESSON CORPORATION$24.6B
- 2. EXELAN PHARMACEUTICALS INC$100.2M
- 3. PROGENICS PHARMACEUTICALS INC$85.0M
- 4. CARDINAL HEALTH 414, LLC$61.3M
- 5. NOVARTIS PHARMACEUTICALS CORPORATION$55.3M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.